The University of Massachusetts Medical School's MassBiologics laboratory has received a milestone payment from pharmaceutical manufacturer Merck. The move comes after the launch of a Phase-III clinical trial of an antibody combination drug used to treat Clostridium difficile, a gastro-intestinal bacterium, according to a UMass Medical School statement.
The drug was developed by MassBiologics and Medarex, a biotechnology division of Bristol Myers Squibb based in Princeton, N.J., and licensed by Merck.
The amount of Merck's payment was not disclosed. Merck intends to file for FDA approval of the drug in 2014, according to a spokesman for UMass Medical School.